Munich Cancer Registry



- Incidence and Mortality
- Selection Matrix
- Homepage
- Deutsch

ICD-10 D09.0, D41.4: Bladder tumor

Year of diagnosis	1988-1997	1998-2014
Patients	1,998	8,633
Diseases	1,998	8,638
Cases evaluated	1,778	6,611
Creation date	03/02/2016	
Export date	12/23/2015	
Population	4.64 m	



Munich Cancer Registry at Munich Cancer Center Marchioninistr. 15 Munich, 81377 Germany

http://www.tumorregister-muenchen.de/en

http://www.tumorregister-muenchen.de/en/facts/surv/sD0941E-ICD-10-D09.0-D41.4-Bladder-tumor-survival.pdf

Survival




Figure 1a. Relative survival of patients with bladder tumor by period of diagnosis. Included in the evaluation are 8,346 cases diagnosed between 1988 and 2014.

The presented survival curves are derived from clinical records with valid follow-up informations, which means that death certificate cases (DCO) cases are omitted from the analysis. With this one restriction, the MCR has provided populationbased statistics since 1998, collecting data on all cancer cases in the region of southern Bavaria. Historical data of previous time periods can be heavily selected, therefore, univariate survival comparisons of the presented time periods must be carefully considered. Nonetheless, all calculable survival curves are depicted to facilitate the comparison of long time follow-up analyses of relative survival between particular cancers.

	F	Period	of diag	gnosis		
	1988-	1997	1998-	2006	200)7+
	n=1,	777	n=2,	895	n=3	,674
Years						
0	100.0	100.0	100.0	100.0	100.0	100.0
1	95.5	99.7	96.2	99.6	95.6	99.0
2	90.4	98.4	92.7	99.6	91.4	98.2
3	86.3	97.9	88.2	98.5	87.3	97.1
4	81.6	96.3	84.1	97.5	83.7	96.0
5	77.9	95.7	80.0	96.1	79.6	95.1
6	73.4	93.5	76.3	95.0	75.4	93.4
7	70.2	93.1	72.1	93.3	71.4	91.5
8	65.7	90.6	68.7	92.2		
9	61.9	88.6	64.9	90.4		
10	58.1	86.3	61.2	88.5		
11	54.8	84.5	58.2	87.5		
12	51.1	81.6	54.7	85.5		
13	47.6	78.9	50.6	82.1		
14	44.5	76.5	46.4	78.4		
15	41.9	74.5	43.4	76.2		
		72.4				
	0 1 2 3 4 5 6 7 8 9 10 11 12 13 14	1988-n=1,yearsobs. %0100.0195.5290.4386.3481.6577.9673.4770.2865.7961.91058.11154.81251.11347.61444.51541.91639.11736.31834.51932.1	1988-1997 Years obs. % rel. % 0 100.0 100.0 1 95.5 99.7 2 90.4 98.4 3 86.3 97.9 4 81.6 96.3 5 77.9 95.7 6 73.4 93.5 7 70.2 93.1 8 65.7 90.6 9 61.9 88.6 10 58.1 86.3 11 54.8 84.5 12 51.1 81.6 13 47.6 78.9 14 44.5 76.5 15 41.9 74.5 16 39.1 72.4 17 36.3 69.8 18 34.5 68.9 19 32.1 66.3	1988-1997 1998-1997 Years obs. % rel. % obs. % 0 100.0 100.0 100.0 1 95.5 99.7 96.2 2 90.4 98.4 92.7 3 86.3 97.9 88.2 4 81.6 96.3 84.1 5 77.9 95.7 80.0 6 73.4 93.5 76.3 7 70.2 93.1 72.1 8 65.7 90.6 68.7 9 61.9 88.6 64.9 10 58.1 86.3 61.2 11 54.8 84.5 58.2 12 51.1 81.6 54.7 13 47.6 78.9 50.6 14 44.5 76.5 46.4 15 41.9 74.5 43.4 16 39.1 72.4 74.5 17 36.3 69.8	1988-19971998-2006 $n=1,777$ 1998-2006 $n=2,895$ Yearsobs.%rel.%obs.%rel.%0100.0100.0100.0100.0195.599.796.299.6290.498.492.799.6386.397.988.298.5481.696.384.197.5577.995.780.096.1673.493.576.395.0770.293.172.193.3865.790.668.792.2961.988.664.990.41058.186.361.288.51154.884.558.287.51251.181.654.785.51347.678.950.682.11444.576.546.478.41541.974.543.476.21639.172.476.276.31834.568.976.276.31932.166.376.376.3	n=1,777n=2,895n=3, obs.%Yearsobs.%rel.%obs.%rel.%obs.%rel.%obs.%0100.0100.0100.0100.0100.0100.0195.599.796.299.695.6290.498.492.799.691.4386.397.988.298.587.3481.696.384.197.583.7577.995.780.096.179.6673.493.576.395.075.4770.293.172.193.371.4865.790.668.792.271.4961.988.664.990.471.41058.186.361.288.571.41154.884.558.287.571.41251.181.654.785.571.41347.678.950.682.176.21444.576.546.478.476.21639.172.476.276.276.21834.568.976.276.276.21932.166.376.576.576.5

Table 1b. Observed (obs.) and relative (rel.) survival of patients with bladder tumor by period of diagnosis for period 1988-2014 (N=8,346).




Figure 2a. Survival of patients with bladder tumor by gender. Included in the evaluation are 8,346 cases diagnosed between 1988 and 2014.

	C	Sende	r	
	Ma	ale	Ferr	nale
	n=6,	260	n=2,	086
Years	obs. %	rel. %	obs. %	rel. %
0	100.0	100.0	100.0	100.0
1	95.8	99.5	95.8	99.0
2	91.6	99.0	91.8	98.0
3	87.3	98.2	87.6	96.7
4	83.0	97.0	84.1	95.6
5	78.8	95.7	80.7	95.1
6	74.6	94.2	77.0	93.6
7	70.6	92.6	73.9	92.8
8	66.6	90.7	70.4	91.8
9	62.8	89.0	66.6	89.7
10	58.8	86.7	63.4	88.4
11	55.7	85.3	60.4	87.0
12	51.7	82.4	57.6	85.8
13	48.3	80.0	52.7	81.4
14	45.1	77.5	48.4	77.4
15	42.2	75.5	45.8	75.7
16	39.4	73.1	42.6	73.0
17	36.4	70.2	40.7	71.9
18	34.6	69.3	38.6	71.1
19	32.2	66.8	35.6	67.8
20	29.9	64.6	33.2	64.9

Table 2b. Observed (obs.) and relative (rel.) survival of patients with bladder tumor by gender for period 1988-2014 (N=8,346).




Figure 3a. Observed survival of patients with bladder tumor by age category. Included in the evaluation are 8,346 cases diagnosed between 1988 and 2014.




Figure 3b. Relative survival of patients with bladder tumor by age category. Included in the evaluation are 8,346 cases diagnosed between 1988 and 2014.

Age category	Age category													
0-49 yrs 50-59 yrs 60-69 yrs 70-79	yrs 80-	+ yrs												
n=599 n=1,295 n=2,325 n=2,63	37 n=1	1,490												
Years obs. % rel. % obs. % rel. % obs. % rel. % obs. % rel. %	rel. % obs. %	o rel. %												
	100.0 100.0	100.0												
1 99.8 99.9 99.8 99.9 97.6 99.2 95.8	99.6 87.9													
2 99.6 99.9 98.5 99.9 95.9 99.0 90.9	98.6 76.9	96.7												
3 99.2 99.9 97.1 99.2 93.4 98.3 86.0	97.8 66.8	95.8												
4 98.6 99.6 95.8 98.9 90.5 97.2 81.6	97.4 57.3	93.8												
5 97.9 99.2 94.5 98.4 87.5 96.0 76.3	96.4 50.0	93.8												
6 97.4 99.2 92.5 97.5 84.9 95.4 70.1	94.3 43.5	93.8												
7 96.9 98.8 91.3 97.3 81.6 93.8 65.8	94.0 35.7													
8 96.6 98.8 89.4 96.3 79.0 93.5 60.2	93.4 29.4	91.7												
9 95.6 98.4 88.0 96.1 75.3 91.5 55.5	92.8 23.4	88.2												
10 95.3 98.4 86.1 95.3 72.1 90.7 49.9	91.1 18.0	83.4												
11 94.5 98.2 84.6 95.0 68.6 89.3 46.2	91.1													
12 93.3 97.6 82.0 93.5 65.0 87.8 40.9	91.1													
13 92.8 97.5 79.9 92.7 61.0 85.6 34.7	86.9													
14 92.2 97.5 78.0 92.2 56.8 83.6 29.3	83.1													
15 89.3 95.4 76.5 92.1 54.6 83.4 24.3	78.7													
16 88.7 95.4 74.1 91.3 50.6 82.5 19.5	72.7													
17 87.9 95.4 71.8 90.6 46.7 81.1 15.8	67.2													
18 87.9 95.4 70.2 90.5 44.8 81.1														
19 87.9 95.4 67.2 88.5 40.3 79.5														
20 87.9 95.4 63.3 86.7 36.5 77.3														

Table 3c. Observed (obs.) and relative (rel.) survival of patients with bladder tumor by age category for period 1988-2014 (N=8,346).




Figure 4a. Relative survival of patients with bladder tumor by UICC. For 8,210 of 8,346 cases diagnosed between 1988 and 2014 valid data could be obtained for this item. For a total of 1,047 cases an evaluable classification was established. The grey line represents the subgroup of 7,299 patients with missing values regarding UICC (87.5% of 8,346 patients, the percent values of all other categories are related to n=1,047). Subgroups with sample size <15 are dropped from the chart.

					UICC					
	Ta/	Tis	I		I	I	IV	/	NA/	NOS
	n=1,	,040	n=	=2	n=2		n=3		n=7,299	
Years	obs. %	rel. %	obs. %	rel. %						
0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0
1	95.6	99.4							95.8	99.5
2	92.6	100.0							91.5	98.6
3	88.8	99.7							87.2	97.5
4	84.0	97.9							83.2	96.6
5	80.0	96.7							79.2	95.4
6	75.9	95.3							75.1	93.9
7	72.6	94.7							71.2	92.4
8	67.9	92.0							67.6	91.0
9	64.2	90.0							63.8	89.3
10	61.4	89.2							59.8	86.8

Table 4b. Observed (obs.) and relative (rel.) survival of patients with bladder tumor by UICC for period 1988-2014 (N=1,047).




Figure 4c. Relative survival of patients with bladder tumor by UICC. For 6,438 of 6,569 cases diagnosed between 1998 and 2014 valid data could be obtained for this item. For a total of 403 cases an evaluable classification was established. The grey line represents the subgroup of 6,166 patients with missing values regarding UICC (93.9% of 6,569 patients, the percent values of all other categories are related to n=403). Subgroups with sample size <15 are dropped from the chart.

					UICC					
	Ta/	Tis	1		I	I	IV	/	NA/NOS	
	n=3	397	n=2		n=2		n=2		n=6	166
Years	obs. %	rel. %								
0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0
1	97.2	100.4							95.8	99.4
2	95.7	102.0							91.8	98.7
3	92.3	101.9							87.4	97.5
4	88.5	101.0							83.5	96.6
5	83.6	99.0							79.4	95.3
6	80.0	98.1							75.6	94.0
7	75.8	96.3							71.5	92.3
8	72.1	94.8							68.1	91.2
9	68.7	93.7							64.4	89.5
10	66.0	92.8							60.5	87.5

Table 4d. Observed (obs.) and relative (rel.) survival of patients with bladder tumor by UICC for period 1998-2014 (N=403).




Figure 4e. Relative survival of patients with bladder tumor by TNM staging. For 8,210 of 8,346 cases diagnosed between 1988 and 2014 valid data could be obtained for this item. For a total of 8,209 cases an evaluable classification was established. The accumulated percentage exceeds the 100% value because patients are potientially considered in more than one subgroup. The grey line represents the subgroup of 137 patients with missing values regarding TNM staging (1.6% of 8,346 patients, the percent values of all other categories are related to n=8,209). Subgroups with sample size <15 are dropped from the chart.

	TNM staging													
	Ta/Tis		T1		T2		N	0	N	+	NX		MO	
	n=8,	186	n=	10	n=8		n=1,736		n=2		n=2,159		n=1,	,708
Years	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %
0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0
1	95.9	99.6					96.0	99.6	100.0	89.9	96.3	100.1	96.1	99.8
2	91.8	98.9					92.2	99.3	100.0	79.7	92.3	99.6	92.5	99.7
3	87.5	97.9					88.2	98.6	100.0	69.6	88.5	99.1	88.7	99.2
4	83.4	96.8					84.1	97.6	100.0	59.5	84.6	98.3	84.5	98.0
5	79.4	95.7					80.0	96.2			80.8	97.6	80.3	96.7
6	75.4	94.3					75.6	94.4			77.5	97.1	76.1	95.1
7	71.6	93.0					72.1	93.4			73.6	95.7	72.6	94.1
8	67.7	91.3					67.5	90.8			70.0	94.6	68.4	92.0
9	63.9	89.5					63.6	88.7			66.0	92.7	65.0	90.7
10	60.1	87.4					60.7	87.8			61.2	89.2	61.9	89.5

	TN	M stag	ing	
cont'd	Μ	-	NA/N	NOS
	n=	=3	n=1	37
Years	obs. %	rel. %	obs. %	rel. %
0	100.0	100.0	100.0	100.0
1			91.9	95.2
2			85.8	91.9
3			81.8	90.4
4			79.3	89.8
5			76.3	89.2
6			68.6	82.1
7			64.1	78.5
8			59.9	76.1
9			59.9	75.6
10			59.9	75.0

Table 4f. Observed (obs.) and relative (rel.) survival of patients with bladder tumor by TNM staging for period 1988-2014 (N=13,812).






Figure 4g. Relative survival of patients with bladder tumor by TNM staging. For 6,438 of 6,569 cases diagnosed between 1998 and 2014 valid data could be obtained for this item. For a total of 6,437 cases an evaluable classification was established. The accumulated percentage exceeds the 100% value because patients are potientially considered in more than one subgroup. The grey line represents the subgroup of 132 patients with missing values regarding TNM staging (2.0 % of 6,569 patients, the percent values of all other categories are related to n=6,437). Subgroups with sample size <15 are dropped from the chart.

	TNM staging													
	Ta/	Tis	Т	1	T2		N	0	N	+	N	Х	MO	
	n=6,	414	n=	10	n=8		n=884		n=1		n=1,477		n=791	
Years	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %
0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0
1	96.0	99.6					96.8	99.9	100.0	75.3	96.3	99.9	97.4	100.6
2	92.2	99.1					94.0	100.3	100.0	50.5	93.0	99.9	94.6	100.9
3	87.8	97.9					90.5	99.7	100.0	25.8	89.4	99.5	91.6	100.8
4	83.9	97.0					87.4	99.6	100.0	1.0	85.7	99.0	88.1	100.3
5	79.8	95.7					82.9	97.8			81.7	97.9	83.2	97.9
6	76.1	94.6					79.1	96.6			78.8	97.9	79.7	97.1
7	72.0	92.9					74.7	94.4			74.4	95.9	75.6	95.2
8	68.6	91.8					70.2	91.9			71.4	95.4	71.4	92.9
9	64.8	90.1					66.4	90.1			67.7	93.9	68.9	92.9
10	61.0	88.2					63.6	89.4			62.9	90.8	66.0	92.1

TNM staging												
cont'd	Μ	1 -	NA/NOS									
	n=	=2	n=132									
Years	obs. %	rel. %	obs. %	rel. %								
0	100.0	100.0	100.0	100.0								
1			91.6	94.9								
2			85.2	91.4								
3			81.0	89.6								
4			78.4	88.9								
5			75.3	88.0								
6			67.0	80.1								
7			63.7	77.8								

Table 4h. Observed (obs.) and relative (rel.) survival of patients with bladder tumor by TNM staging for period 1998-2014 (N=9,587).




Figure 4i. Conditional relative 5-year survival of patients with bladder tumor by extent of disease. For 8,210 of 8,346 cases diagnosed between 1988 and 2014 valid data could be obtained for this item. For a total of 435 cases an evaluable classification was established. The grey line represents the subgroup of 7,911 patients with missing values regarding extent of disease (94.8% of 8,346 patients, the percent values of all other categories are related to n=435). Subgroups with sample size <15 are dropped from the chart.

			Exten	t of dis	sease				
		Local Cond. surv. %		Regional Cond. surv. %		ant Cond. surv. %	NA/NOS Cond. surv. %		
Years	n	5 yrs	n	5 yrs	n	5 yrs	n	5 yrs	
0	430	91.5	2		3		7,911	95.8	
1	371	96.2					7,165	95.1	
2	325	97.1					6,446	95.0	
3	298	93.1					5,749	95.1	
4	263	92.1					5,070	95.0	
5	233	96.9					4,461	94.3	
6	203	92.8					3,860	95.0	
7	178	91.9					3,354	94.1	
8	143	88.9					2,816	93.0	
9	123	84.5					2,433	92.0	
10	110	79.2					2,063	92.5	

Table 4j. Conditional relative 5-year survival of patients with bladder tumor by extent of disease for period 1988-2014 (N=435).

Conditional relative survival rates refer to the relative survival probability, in this case for 5 years after cancer diagnosis, compared to the age- and sex-matched population (=100%) under the condition of being alive for a certain time period (x-axis in Figure 4g). The results illustrate to what extent the cancer induced mortality of particular subgroups declines in the subsequent years after detection of the malignancy. For instance, according to the presented survival statistics, patients in the subgroup extent of disease="Local", who are alive at least 3 years after cancer diagnosis, the conditional relative 5-year survival rate is 93.1% (n=298).

Shortcuts

MCR	Munich Cancer Registry, Germany								
NCI	National Cancer Institute, USA								
SEER	Surveillance, Epidemiology, and End Results, USA								
UICC	Union for International Can	cer Control, Geneva							
DCO	Death certificate only	Death certificate provides the only notification to the registry.							
NA	Not available								
NOS	Not otherwise specified								
OS	Overall/Observed survival	Overall/Observed survival (Kaplan-Meier estimate) Date of entry: diagnosis Event: death from any cause							
RS	Relative survival	Survival compared to "general population", ratio of observed to expected survival (Ederer II method), reflecting cancer specific survival							
AS	Assembled survival	Assembled chart of observed, expected, relative survival							
CS	Conditional survival	Survival probability under the condition of surviving a given period of time							
TTP	Time to progression	Time to first progression / relapse Date of entry: diagnosis Event: (progression / relapse): first local-, lymph node recurrence, distant metastasis or unspecified progression							
	1-КМ	1 minus Kaplan-Meier estimator ("inverse" Kaplan-Meier estimator)							
	CI	Cumulative incidence Death as competing risk (according to Kalbfleisch und Prentice)							
PPS	Post-progression survival	Survival since first progression / relapse (Kaplan-Meier estimate) Date of entry (progression / relapse): first local-, lymph node recurrence, distant metastasis or unspecified progression Event: death from any cause							

Recommended Citation

Munich Cancer Registry. Survival ICD-10 D09.0, D41.4: Bladder tumor [Internet]. 2016 [updated 2016 Mar 2; cited 2016 May 1]. Available from: http://www.tumorregister-muenchen.de/en/facts/surv/sD0941E-ICD-10-D09.0-D41.4-Bladder-tumor-survival.pdf

Copyright

The content of the public web site provided by the Munich Cancer Registry is available worldwide and free of charge. All documents are free to download, utilize, copy, print-out and distribute, providing that the MCR is referenced.

Disclaimer

The Munich Cancer Registry reserves the right to not be responsible for the topicality, correctness, completeness or quality of the information provided. Liability claims regarding damage caused by the use of any information provided, including any kind of information which is incomplete or incorrect, will therefore be rejected.

Index of figures and tables

Fig /Thl Dago		
Fig./Tbl.		Page
1a	Relative survival by period of diagnosis (chart)	2
1b	Survival by period of diagnosis (table)	2
2a	Survival by gender (chart)	3
2b	Survival by gender (table)	3
3a	Observed survival by age category (chart)	4
3b	Relative survival by age category (chart)	4
3c	Survival by age category (table)	5
4a	Relative survival by UICC 1988+ (chart)	6
4b	Survival by UICC 1988+ (table)	6
4c	Relative survival by UICC 1998+ (chart)	7
4d	Survival by UICC 1998+ (table)	7
4e	Relative survival by TNM staging 1988+ (chart)	8
4f	Survival by TNM staging 1988+ (table)	8
4g	Relative survival by TNM staging 1998+ (chart)	10
4h	Survival by TNM staging 1998+ (table)	10
4i	Conditional survival by extent of disease (chart)	12
4j	Conditional survival by extent of disease (table)	12